valyl-glycyl-valyl-alanyl-prolyl-glycine profile

valyl-glycyl-valyl-alanyl-prolyl-glycine: repeating peptide chemotactic for fibroblasts & monocytes [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	124934
SCHEMBL ID	1404295
MeSH ID	M0125797

Synonym
vgvapg
2-[[(2s)-1-[(2s)-2-[[(2s)-2-[[2-[[(2s)-2-amino-3-methylbutanoyl]amino]acetyl]amino]-3-methylbutanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]acetic acid
92899-39-3
valyl-glycyl-valyl-alanyl-prolyl-glycine
glycine, n-(1-(n-(n-(n-l-valylglycyl)-l-valyl)-l-alanyl)-l-prolyl)-, (sp-4-2)-
04v1qpj5tw ,
val-gly-ala-pro-gly
unii-04v1qpj5tw
SCHEMBL1404295
hexapeptide-12 (val-gly-val-ala-pro-gly) [inci]
hexapeptide-12 (val-gly-val-ala-pro-gly)
glycine, l-valylglycyl-l-valyl-l-alanyl-l-prolyl-
val-gly-val-ala-pro-gly
dermaxyl
chemotactic domain of elastin
chemotactic domain of elastin (h-l-val-gly-l-val-l-ala-l-pro-gly-oh)
mfcd00133914
DTXSID50918909
n-[(1-{n-[2-({2-[(2-amino-1-hydroxy-3-methylbutylidene)amino]-1-hydroxyethylidene}amino)-1-hydroxy-3-methylbutylidene]alanyl}pyrrolidin-2-yl)(hydroxy)methylidene]glycine
Q27247699
l-glycine high
l-glycine7407
l-glycine high7408

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	2 (5.41)	18.7374
1990's	6 (16.22)	18.2507
2000's	9 (24.32)	29.6817
2010's	11 (29.73)	24.3611
2020's	9 (24.32)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (2.70%)	5.53%
Reviews	2 (5.41%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	34 (91.89%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
alanylalanine alanylalanine: RN given refers to (DL)-isomer	2.17	1	dipeptide
dihydroxyphenylalanine Dihydroxyphenylalanine: A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific.. dopa : A hydroxyphenylalanine carrying hydroxy substituents at positions 3 and 4 of the benzene ring.	2.04	1	hydroxyphenylalanine; non-proteinogenic alpha-amino acid; tyrosine derivative	human metabolite
verapamil Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.	2.41	1	aromatic ether; nitrile; polyether; tertiary amino compound
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source	2.04	1	chromones; morpholines; organochlorine compound	autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector
nifedipine Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.	2.41	1	C-nitro compound; dihydropyridine; methyl ester	calcium channel blocker; human metabolite; tocolytic agent; vasodilator agent
xanthenes Xanthenes: Compounds with three aromatic rings in linear arrangement with an OXYGEN in the center ring.	2.25	1	xanthene
resazurin resazurin: used as indicator in detection of hyposulfite (sulfoxylate); in food research (reductase test); structure	2.25	1	phenoxazine
rosiglitazone [no description available]	2.25	1	aminopyridine; thiazolidinediones	EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; insulin-sensitizing drug
prolyl-glycyl-glycine prolyl-glycyl-glycine: structure given in first source	2.25	1	oligopeptide
arginyl-glycyl-aspartyl-serine arginyl-glycyl-aspartyl-serine: corresponds to cell attachment site of fibronectin; located near carboxyl-terminal region of alpha-chain of fibrinogen; inhibits platelet aggregation & fibrinogen binding to activated platelets	2.13	1
elastin [no description available]	5.86	29	oligopeptide
n-formylmethionine leucyl-phenylalanine N-Formylmethionine Leucyl-Phenylalanine: A formylated tripeptide originally isolated from bacterial filtrates that is positively chemotactic to polymorphonuclear leucocytes, and causes them to release lysosomal enzymes and become metabolically activated.. N-formyl-L-methionyl-L-leucyl-L-phenylalanine : A tripeptide composed of L-Met, L-Leu and L-Phe in a linear sequence with a formyl group at the amino terminus. It acts as a potent inducer of leucocyte chemotaxis and macrophage activator as well as a ligand for the FPR receptor.	2.01	1	tripeptide
dizocilpine maleate Dizocilpine Maleate: A potent noncompetitive antagonist of the NMDA receptor (RECEPTORS, N-METHYL-D-ASPARTATE) used mainly as a research tool. The drug has been considered for the wide variety of neurodegenerative conditions or disorders in which NMDA receptors may play an important role. Its use has been primarily limited to animal and tissue experiments because of its psychotropic effects.. dizocilpine maleate : A maleate salt obtained by reaction of dizocilpine with one equivalent of maleic acid.	2.41	1	maleate salt; tetracyclic antidepressant	anaesthetic; anticonvulsant; neuroprotective agent; nicotinic antagonist; NMDA receptor antagonist
valyl-prolyl-glycyl-valyl-glycine valyl-prolyl-glycyl-valyl-glycine: a synthetic elastin peptide; do not confuse with polymeric VPGVG	1.98	1
valyl-alanyl-prolyl-glycine valyl-alanyl-prolyl-glycine: an elastin tetrapeptide; serves as a quantitative measure for human elastins; RN refers to all-L isomer	2.04	1

Condition	Relationship Strength	Studies	Trials
Benign Neoplasms [description not available]	2.41	1	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	2.41	1	0
Innate Inflammatory Response [description not available]	2.72	2	0
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.72	2	0
Neuroblastoma A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)	3.04	3	0
Degenerative Diseases, Central Nervous System [description not available]	2.6	1	0
Neurodegenerative Diseases Hereditary and sporadic conditions which are characterized by progressive nervous system dysfunction. These disorders are often associated with atrophy of the affected central or peripheral nervous system structures.	2.6	1	0
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	2.5	2	0
Airflow Obstruction, Chronic [description not available]	3.7	1	1
Pulmonary Disease, Chronic Obstructive A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.	3.7	1	1
Malignant Melanoma [description not available]	2.47	2	0
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	2.47	2	0
Pulmonary Arterial Remodeling [description not available]	2.1	1	0
Blood Clot [description not available]	2.1	1	0
Thrombosis Formation and development of a thrombus or blood clot in the blood vessel.	2.1	1	0
Astrocytoma, Grade IV [description not available]	2.05	1	0
Invasiveness, Neoplasm [description not available]	2.45	2	0
Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.	2.05	1	0
Atherogenesis [description not available]	2.45	2	0
Aneurysm, Aortic [description not available]	2.05	1	0
Arterial Diseases, Carotid [description not available]	2.05	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.7	3	0
Aortic Aneurysm An abnormal balloon- or sac-like dilatation in the wall of AORTA.	2.05	1	0
Carotid Artery Diseases Pathological conditions involving the CAROTID ARTERIES, including the common, internal, and external carotid arteries. ATHEROSCLEROSIS and TRAUMA are relatively frequent causes of carotid artery pathology.	2.05	1	0
Atherosclerosis A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.	2.45	2	0
Hyperplasia An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.	2.03	1	0
Disease Exacerbation [description not available]	2.04	1	0
Angiogenesis, Pathologic [description not available]	2.92	4	0
Cancer of Skin [description not available]	2.04	1	0
Skin Neoplasms Tumors or cancer of the SKIN.	2.04	1	0
Cancer of Lung [description not available]	2.38	2	0
Lung Neoplasms Tumors or cancer of the LUNG.	2.38	2	0
Abdominal Aortic Aneurysm [description not available]	2.69	3	0
Aortic Aneurysm, Abdominal An abnormal balloon- or sac-like dilatation in the wall of the ABDOMINAL AORTA which gives rise to the visceral, the parietal, and the terminal (iliac) branches below the aortic hiatus at the diaphragm.	2.69	3	0
Metastase [description not available]	2.89	1	0
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	2.89	1	0

valyl-glycyl-valyl-alanyl-prolyl-glycine

Description

Cross-References

Synonyms (23)

Research

Studies (37)

Market Indicators

Research Demand Index: 11.36

Study Types

valyl-glycyl-valyl-alanyl-prolyl-glycine

Description

Cross-References

Synonyms (23)

Research

Studies (37)

Market Indicators

Research Demand Index: 11.36

Study Types

Related Drugs (15)

Related Conditions (36)